215600 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
SillaJen, Inc. develops oncolytic immunotherapeutics virus. Its products include pexa-vec and JX-929. The company was founded on March 28, 2006 and is headquartered in Busan, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
215600 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company